Dementia
An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.
Subtype terms (11)
More specific conditions that are subtypes of Dementia in the MeSH hierarchy.
- AIDS Dementia Complex
21 drugs (16 approved, 5 experimental)
- Alzheimer Disease
734 drugs (229 approved, 505 experimental)
- Aphasia, Primary Progressive
6 drugs (5 approved, 1 experimental)
- Creutzfeldt-Jakob Syndrome
1 drug experimental
- Dementia, Vascular
51 drugs (32 approved, 19 experimental)
- Diffuse Neurofibrillary Tangles with Calcification
- Frontotemporal Lobar Degeneration
7 drugs (6 approved, 1 experimental)
- Huntington Disease
97 drugs (44 approved, 53 experimental)
- Kluver-Bucy Syndrome
- Lewy Body Disease
46 drugs (24 approved, 22 experimental)
- Mixed Dementias
Drugs by status
Approved for this indication (10)
Phase 4 trials (47)
- melatonin
- hydrocodone
- propofol
- efavirenz
- dabigatran
- paroxetine
- ketamine
- citalopram
- methylphenidate
- valproic acid
- duloxetine
- folic acid
- sevoflurane
- escitalopram
- sertraline
- tenofovir
- haloperidol
- warfarin
- amantadine
- ioflupane i-123
- lamivudine
- lemborexant
- lithium
- metaiodobenzylguanidine
- nimodipine
- nevirapine
- olanzapine
- atorvastatin
- acetaminophen
- prazosin
- +17 more
Phase 3 trials (98)
- flupentixol
- phenobarbital
- piracetam
- methylprednisolone
- nav4694
- florbetapir
- acamprosate
- agomelatine
- amitriptyline
- LECANEMAB
- buspirone
- alprazolam
- biperiden
- bromperidol
- lamotrigine
- chlorprothixene
- clobazam
- emineurina
- clonazepam
- clozapine
- diphenhydramine
- encenicline
- cannabidiol
- fluphenazine
- flurazepam
- fluspirilene
- flutemetamol F-18
- fluvoxamine
- gabapentin
- gantenerumab
- +68 more
Phase 2 trials (49)
- roflumilast
- bacille calmette-guerin
- nabilone
- alpha-lipoic acid
- d-ribose
- amlodipine
- insulin human
- deferiprone
- ladostigil hemitartrate
- dronabinol
- rimabotulinumtoxinB
- nic5-15
- oleoylestrone
- rifaximin
- sitagliptin
- secoisolariciresinol
- sodium benzoate
- rotigotine
- tetrahydrocannabinol
- rasagiline
- nicotinamide
- xanamem
- ampakine
- losartan
- angelica
- latrepirdine
- omega-3 fatty acids
- jnj-63733657
- fish oil
- nicorandil
- +19 more
Phase 1 trials (21)
Other trials (27)
- nitrous oxide
- florbetaben F-18
- vitamin d3
- sucrose
- cocoa bean
- dark chocolate
- progesterone
- vitis vinifera
- isoflurane
- liraglutide
- lavender
- ropivacaine
- lidocaine
- levobupivacaine
- celecoxib
- sunflower oil
- desflurane
- masupirdine
- bupivacaine
- glucose
- fentanyl
- estrogen
- docosahexaenoic acid
- eicosapentanoic acid
- threonate
- jing-si
- carpalatine
Organizations
Organization Involved with Phase 4 Indications (60)
- Abbott
- Cephalon
- Ipsen
- Ever Neuro Pharma GmbH
- Boehringer Ingelheim
- Otsuka
- National Institute of Mental Health (NIMH)
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institute on Aging (NIA)
- University of Pittsburgh
- Allegiance Health
- University of London
- Harvard University
- Diakonhjemmet Hospital
- Emory University
- Helse Møre og Romsdal HF
- Indiana University
- Johns Hopkins University
- Northwestern University
- Seoul National University
- Sykehuset Innlandet HF
- Universidad Autonoma de Nuevo Leon
- University of Nebraska
- University of Oslo
- University of Rochester
- University of Toronto
- University of Bergen
- Mayo Clinic
- Chinese University of Hong Kong
- East Kent Hospitals University NHS Foundation Trust
- +30 more
Organization Involved with Phase 3 Indications (87)
- Acadia Pharmaceuticals
- Avid Radiopharmaceuticals
- Shire
- Bristol-Myers Squibb
- Roche
- ViiV Healthcare
- AstraZeneca
- Eli Lilly
- Pfizer
- Sanofi
- Avanir
- Axsome Therapeutics, Inc.
- Glaxo Wellcome
- Merz
- Myrexis Inc.
- Neurological Research Center
- Shineway Pharmaceutical Co.,Ltd
- Solvay
- TauRx Therapeutics Ltd
- Whanin Pharmaceutical Company
- Rottapharm
- National Institute of Allergy and Infectious Diseases (NIAID)
- University of Pennsylvania
- Hebei University
- Bangor University
- Boston University
- Cancer Research UK
- Cornell University
- Georgetown University
- Newcastle University
- +57 more
Organization Involved with Phase 2 Indications (108)
- AC Immune SA
- Actinogen Medical
- Targacept
- Elan Pharmaceuticals
- Biogen
- Purdue Pharmaceuticals
- Anavex Life Sciences Corp.
- Avraham Pharmaceuticals Ltd
- Biotie Therapies
- Charsire Biotechnology Corp.
- Chase Pharmaceuticals Corporation
- Cognitive Research Corporation
- Dong-A Pharmaceutical
- EIP Pharma, LLC
- FORUM Pharmaceuticals Inc
- Heptares Therapeutics Limited
- Humanetics Corporation
- Mediti Pharma Inc.
- Regenera Pharma Ltd
- Sage Therapeutics
- Sinphar Pharmaceutical Co., Ltd
- Sosei
- Tobira Therapeutics, Inc.
- Teva
- A2 Healthcare Taiwan Corporation
- Shanghai Hutchison Pharmaceuticals Limited
- Transition Therapeutics
- The Dana Foundation
- Michael J. Fox Foundation for Parkinson's Research
- ZonMw: The Netherlands Organisation for Health Research and Development
- +78 more
Organization Involved with Phase 1 Indications (18)
- Miles
- Merck
- Centaur Pharmaceuticals
- Hearthstone Alzheimer Care
- Molecular NeuroImaging
- Parexel
- Enterin Inc.
- Medipost Co Ltd.
- Kessler Foundation
- Institute for Neurodegenerative Disorders
- Mclean Hospital
- Neurological Associates of West Los Angeles
- University of Southern California
- University of Utah
- California Clinical Trials
- BioClinica, Inc.
- Consortium of Canadian Centres for Clinical Cognitive Research
- Spier Family Foundation
Organization Involved with Other Experimental Indications (18)
- GenMont Biotech Incorporation
- I.R.C.C.S. Fondazione Santa Lucia
- China Academy of Chinese Medical Sciences
- McMaster University
- New York University
- Osaka University
- Stanford University
- Swansea University
- University of Zurich
- University of Mannheim
- University of Nice Sophia Antipolis
- Northgate and Prudhoe NHS Trust
- American Diabetes Association
- Waid City Hospital, Zurich
- Magceutics, Inc.
- Fondation de France
- The Alzheimer Society London and Middlesex
- Clinica Luganese Moncucco